Overview of novel restore and target treatment approach to classical Hodgkin lymphoma
How will biosimilars save us money?
Can ibrutinib be used as a first-line treatment in CLL?
Updates from a Phase I clinical trial examining ublituximab in combination with TGR-1202
Naveen Pemmaraju: what to look out for at ASH 2016